The global osteoporosis drugs market accounted for $7,657 million in 2018, and is expected to reach $10,479 million by 2026, registering a CAGR of 3.9% from 2019 to 2026.
Osteoporosis is defined as a medical condition, which is characterized by low density and quality of bones in humans. Furthermore, the bones become porous in this medical condition, which makes them more fragile and, in turn, prone to factures. The condition is caused by over production of the hormone called as parathyroid. The condition can lead to severe fractures, which can have deleterious effects on the health of patient. Therefore, the condition requires treatment, which includes the use of osteoporosis drugs. Some of the drugs available in the market include bisphosphonates selective estrogen inhibitors modulator (SERM), parathyroid hormone therapy, calcitonin, and RANK ligand inhibitors. These drugs are administered through different routes in the body such as orally or intravenously.
The major factor that contributes to the growth of osteoporosis drugs market include rise in prevalence of osteoporosis. Furthermore, other factors that boost the growth of the osteoporosis drugs market are surge in geriatric population across the globe and rise in adoption of sedentary lifestyle worldwide. However, side effects of osteoporosis drugs and the time-consuming drug approval process hamper the growth of osteoporosis drugs market. Conversely, high growth potential in developing economies is expected to offer lucrative opportunities during the forecast period.
Osteoporosis Drugs Market Segmentation
The osteoporosis drugs market size is studied on the basis of drug class, route of administration, and region to provide a detailed assessment of the market. On the basis of drug class, the market is segmented into bisphosphonates, selective estrogen inhibitors modulator (SERM), parathyroid hormone therapy, calcitonin, rank ligand inhibitors, and others. By route of administration, it is segregated into oral, injectable, and others. Region wise, it is analyzed across North America (the U.S., Canada, and Mexico), Europe (Germany, France, the UK, Italy, Spain, and rest of Europe), Asia-Pacific (China, Japan, India, Australia, South Korea, and rest of Asia-Pacific), and LAMEA (Brazil, South Africa, and rest of LAMEA).
Segment Review
By product, the bisphosphonates acquired the major share of osteoporosis drugs market in 2018, owing to increase in investment in R&D of advanced novel bisphosphonates drugs by major players. Furthermore, bisphosphonates are commonly prescribed drugs for the treatment of osteoporosis, which boosts the growth of the market. However, the rank ligand inhibitors segment is expected to exhibit fastest growth rate during the forecast period, owing to the fact that these drugs are used to treat bone metastasis by acting as a chemoattractant to bone for tumor cells that express its receptor, RANK. Thus, the inhibition of the RANKL-RANK pathway serves as an ideal treatment for the bone metastasis.
By Drug Class
Rank Ligand Inhibitor is projected as one of the most lucrative segment.
By route of administration, the oral segment acquired the major share of the osteoporosis drugs market, owing to abundant availability of medications, which are available as oral drugs in the market. Conversely, the injectable segment is expected to grow at the fastest CAGR during the forecast period, owing to factors such as rise in need for drugs, which exhibit improved bioavailability rapid mode of action.
By Route Of Administration
Oral holds a dominant position in 2018 and would continue to maintain the lead over the forecast period.
Region wise, North America accounted for the major share in 2018, and is expected to continue this trend, owing to easy availability of osteoporosis drugs. Moreover, surge in incidence of osteoporosis contributes toward the growth of this market. On the contrary, Asia-Pacific is expected to register the fastest growth during the forecast period attributed to increase in awareness regarding the use of osteoporosis drugs. Moreover, the constantly evolving life science industry drives the growth of the market in the developing economies such as India, China, and Malaysia.
By Region
LAMEA region would exhibit the highest CAGR of 5.5% during 2019-2026.
The global osteoporosis drugs market is highly competitive, and the prominent players in the market have adopted various strategies to garner maximum market share. These include collaboration, product launch, partnership, and acquisition. Major players operating in the market include Amgen Inc., F. Hoffmann-La Roche AG, Radius Health, Inc., Merck & Co. Inc., Novartis International AG (Sandoz), Pfizer Inc., Sun Pharmaceutical Industries Ltd., Takeda Pharmaceutical Company Limited, and Teva Pharmaceutical Industries Ltd.
Key Benefits for Stakeholders:
- This report entails a detailed quantitative analysis along with the current global osteoporosis drugs market trends from 2018 to 2026 to identify the prevailing opportunities along with the strategic assessment.
- The osteoporosis drugs market forecast is studied from 2019 to 2026.
- The osteoporosis drugs market size and estimations are based on a comprehensive analysis of key developments in the industry.
- A qualitative analysis based on innovative products facilitates strategic business planning.
- The development strategies adopted by the key market players are enlisted to understand the competitive scenario of the market
Key Market Segments:
By Drug Class
- Bisphosphonates
- Selective Estrogen Inhibitors Modulator (SERM)
- Parathyroid Hormone Therapy
- Calcitonin
- Rank Ligand Inhibitors
- Others
By Route of Administration
- Oral
- Injectable
- Others
By Region
- North America
- U.S.
- Canada
- Mexico
- Europe
- Germany
- France
- UK
- Italy
- Rest of Europe
- Asia-Pacific
- Japan
- China
- India
- Rest of Asia-Pacific
- LAMEA
- Brazil
- Saudi Arabia
- South Africa
- Rest of LAMEA
Osteoporosis Drugs Market Report Highlights
| Aspects | Details |
 By DRUG CLASS |
|
 By ROUTE OF ADMINISTRATION |
|
 By Region |
|
 Key Market Players | Radius Health, Inc., Novartis International AG (Sandoz), Pfizer Inc., F. HOFFMANN-LA ROCHE LTD., Takeda Pharmaceutical Company Limited, Eli Lilly and Company, Teva Pharmaceutical Industries Ltd., Amgen Inc., Sun Pharmaceutical Industries Ltd., Merck & Co. Inc. |
Analyst Review
Osteoporosis drugs are utilized in the treatment of osteoporosis, which is marked by the presence of weak and porous bones. In addition, osteoporosis requires immediate treatment as the weak bones are highly prone to fractures which can lead to serious harmful effects on the health of the patient. The condition is caused due to the overproduction of hormone parathyroid. Some drugs which are available in the market for the treatment of osteoporosis include bisphosphonates selective estrogen inhibitors modulator (SERM), parathyroid hormone therapy, calcitonin, rank ligand inhibitors, and others.
The utilization of osteoporosis drugs has witnessed a significant growth, owing to surge in incidence of osteoporosis across the globe. The other factors that propel the utilization of different osteoporosis drugs include surge in healthcare expenditure and rise in R&D investments related to osteoporosis drugs. Conversely, stringent governmental regulations related to approval of osteoporosis is a key factor that restricts the growth of the market. However, high market potential offered by developing economies is expected to present lucrative opportunities for the key players during the forecast period.
The total market value of osteoporosis drugs market is $ 7,656.97 million in 2018.
The forcast period for osteoporosis drugs market is 2019 to 2026
The market value of osteoporosis drugs market in 2019 is $8,014.64 million.
The base year is 2018 in osteoporosis drugs market
Top companies such as, Novartis International AG (Sandoz), Amgen Inc., Pfizer Inc., Sun Pharmaceutical Industries Ltd., and Eli Lilly And Company held a high market position in 2018. These key players held a high market postion owing to the strong geographical foothold in different regions.
Rank ligand inhibitors segment is the most influencing segment owing to rise in prevelance of bone cancer as these type of drugs are used in the treatment of bone metastasis. Furthemore, surge in the awareness towards early diagnosis of cancer is another factor that fuels the growth of the market.
The major factor that fuels the growth of the global osteoporosis drugs market is the prevalence of osteoporosis in the widespread elderly population. This lead to surge in demand for drugs used to treat the medical condition.
Asia-Pacific has the highest growth rate in the market which is growing due to the contribution of the following emerging countries such as India with a CAGR of 4.4%. This is due to the improvements in health standards, surge in disposable incomes, and advancements in technology for the development of osteoporosis drugs.
Osteoporosis drugs are defined as therapeutic agents which are utilized in the treatment of osteoporosis. Furthermore, osteoporosis is a serious medical condition which is associated with the presence of fragile bones
Osteoporosis drugs are employed in slowing down the bone brekage and rebuild the damaged bones. Furthemore, there are different type of osteoporosis drugs present in the market such as bisphosphonates, calcitonin, rank ligand inhibitors and others
Loading Table Of Content...
